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SUMMARY
In July 2010, the World Health Organization (WHO) 
released new guidelines entitled, “Antiretroviral 
Drugs for Treating Pregnant Women and Preventing 
HIV Infection in Infants: Towards universal access.” 
Previewed in November 2009 in abridged form, the 
completed document highlights the key WHO 
recommendations for antiretroviral treatment (ART) 
and prophylaxis in pregnant women, and contains 
substantial changes from the 2006 guidelines.  Of 
note, the new guidelines recommend ART for all 
pregnant women with a CD4 cell count (CD4) less 
3than 350 cells/mm , regardless of their clinical stage; 
includes tenofovir (TDF) as an acceptable 
alternative component of an ART regimen in 
pregnant and breastfeeding women; encourages 
initiation of both ART and antiretroviral (ARV) 
prophylaxis early in pregnancy; eliminates single-
dose nevirapine (sdNVP) per se as a prophylaxis 
option; lists three-drug ARV prophylaxis as an 
option for women who do not need ART for their 
own health; and introduces extended daily infant 
nevirapine (ED-NVP) as a strategy for prevention of 
breast milk transmission of HIV. This article reviews 
these new recommendations and their rationale, and 
highlights key implications and challenges to their 
implementation in the Zambian context.
INTRODUCTION
Pediatric HIV infection remains a substantial 
problem worldwide, with close to 400,000 new 
infections occurring yearly primarily as a result of 
1maternal to child transmission.   In Zambia alone, an 
estimated 130,000 children are living with HIV 
infection and another 85,000-90,000 HIV-exposed 
babies are born each year, resulting in an additional 
2
28,000 infections.   While perinatal HIV 
transmission has largely been eliminated in the 
industrialized world, where access to ARVs is nearly 
universal and safe alternatives to breastfeeding 
exist, such drastic reductions have not yet been seen 
in sub-Saharan Africa.  Three challenges stand out 
among many which contribute to the higher rates of 
maternal-to-child HIV transmission in this setting: 
early identification of infected pregnant women, 
timely initiation of effective antepartum prevention, 
and effective prevention during the breastfeeding 
period.  Additionally, the use of sdNVP on its own 
has led to high rates of non-nucleotide reverse 
transcriptase inhibitor (NNRTI)-resistance in both 
3women and children,  resulting in limited – and more 
expensive – treatment options for 
the WHO in their 
recently released “Antiretroviral Drugs for Treating 
Pregnant Women” take a step in the right direction to 
address these issues. 
these patients.  
Although not without their limitations, the 
recommendations provided by 
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Key Recommendations: ART for HIV-infected 
pregnant women who need treatment for their 
own health
Table 1: Summary of Indications for ART in Pregnant 
Women
One obvious implication of these guidelines is that 
all HIV-infected pregnant women need timely CD4 
testing.  This remains a challenge in much of Zambia 
and, until laboratory services can be scaled up to 
meet the demand, it is possible that many women 
who are eligible for ART will be given ARV 
prophylaxis instead. 
The recommended regimens for pregnant women 
requiring ART for their own health are 
The new recommendations for ART initiation in 
newly-identified HIV-infected pregnant women are 
4summarized in Table 1.   While the 2006 WHO 
guidelines recommended ART for pregnant women 
with clinical stage 1 or 2 disease only when the CD4 
5
dropped below 200,  the recommendation for earlier 
treatment is consistent with what has been 
6
recommended in Zambia since 2007.   Importantly, 
these new guidelines state that women who need 
ART for their own heath should start “irrespective of 
gestational age and continue throughout pregnancy, 
4 
delivery, and thereafter”.   This is in contrast to the 
2007 Zambian guidelines, which state that ART 
should not be initiated in women presenting at 36 
6weeks gestation or later.   Adaptation of the WHO 
guidelines should eliminate the confusion providers 
have experienced around the Zambian caveat.
listed in Table 
2.  Including TDF as an alternative option is based 
on the lack of significant associated toxicities found 
7
in pregnancy registry data;  EFV is also included.  
While the guidelines state that EFV should not be 
“newly initiated” during the first trimester, its use in 
pregnancy is otherwise allowed because the benefits 
to the mother and the reduction in transmission are 
4
felt to outweigh the potential toxicity risks.
Table 2:  Recommended Regimens for Pregnant 
Women in Need of ART for their own Health.
st*Note: EFV not to be newly initiated during the 1  
trimester of pregnancy
st
In Zambia, TDF has been part of the preferred 1 -
line ART since 2007; however, many providers have 
been reluctant to initiate women of child-bearing age 
on this drug due to concerns about toxicity in 
pregnancy and the need to switch to an alternative 
agent should pregnancy occur.  The new guidelines 
should reassure providers that TDF can be continued 
during pregnancy and the breastfeeding period. 
Interestingly, “Antiretroviral Drugs for Treating 
Pregnant Women” does not specifically address 
what to do in either of two common clinical 
scenarios: first, which regimen should be used for 
women who need ART for their own health but 
whose CD4 is greater than 250, the threshold above 
which NVP toxicity has commonly been associated; 
and second, what should be done when women 
already on EFV-containing ART become pregnant.  
Concerning the first, the guidelines state that NVP 
can be used for women with a CD4 250-350, but that 
rdan alternative 3  agent should be used if the CD4 is 
greater than 350 due to the known risks of NVP in 
8
such women starting ART.   This first scenario also 
underscores the need to obtain a CD4 count on all 
women before starting therapy. Concerning the 
second, no recommendation is given.  Options 
st
include temporary substitution of EFV during the 1  
trimester with either: a. abacavir (ABC), if the 
woman has been on therapy for at least 6 months 
with documented good adherence and can therefore 
be assumed to be virally suppressed (this option has 
not been studied but presumably should be effective 
at maintaining suppression); b. lopinavir/ritonavir if 
the above-noted conditions are not all met; or c. 
nevirapine if the CD4 remains below 250 (though 
recent data suggest that such a switch may be safe 
after immune reconstitution to even higher CD4 
counts. EFV should be resumed after completion of 
st
the 1  trimester for most women, and appropriate 
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pregnancy prevention measures should be 
instituted immediately post partum in all women 
taking this ARV. 
Women on ART for their own health will obviously 
continue this through the breastfeeding period.  
This should provide effective prophylaxis for the 
infant if ART was started early in pregnancy and the 
mother is adherent, so that viral suppression in both 
the serum and breast milk has occurred.  
Nonetheless, the new WHO guidelines recommend 
some form of infant prophylaxis after delivery for 
infants born to women on ART.  For those who are 
breastfeeding, six weeks of ED-NVP starting from 
birth is recommended; and for those who are not, six 
weeks of either daily AZT or ED-NVP.  Neither 
recommendation is based on data from women on 
ART; the former can probably be justified by the 
fact that some women will be starting ART later in 
pregnancy and viral suppression may not have 
occurred by the time breastfeeding is initiated.   In 
such cases, the ED-NVP will essentially be acting 
as pre-exposure prophylaxis and may provide 
additional protective benefit.  It is not clear that 
AZT or ED-NVP is needed for infants that are not 
breastfeeding when the mother is already on ART; 
however, the recommendation may provide 
coverage for those women planning on replacement 
feeding who end up mix-feeding or breastfeeding 
due to difficulties securing sufficient amounts of 
breast-milk substitute. 
Key Recommendations: ARV prophylaxis for all 
HIV-infected women who do not need treatment 
for their own health 
The new WHO recommendations differ most 
strongly from those of 2006 concerning women 
who do not need ART for their own health.  
Emphasizing the need to provide early access to 
effective prophylaxis, they list two options for these 
women, followed by some type of prophylaxis to 
prevent transmission during the breastfeeding 
period.  Summarized in Table 3, they no longer 
include sdNVP on its own.
Table 3: ARV prophylaxis options recommended 
for women who do not need treatment for their own 
4health
It is important to note that, whichever option is used, 
the new recommendation is for women to start 
taking the prescribed regimen at 14 weeks gestation.  
This shift was motivated by the all-too-common 
scenario of women presenting for their first 
antenatal visit sometime before 28 weeks – the 
previously recommended start time for “short-
course” prophylaxis – only to disappear for the 
remainder of the pregnancy.  Consequently, many 
known HIV-infected mothers have not been 
receiving any prophylaxis at all.  The new 
guidelines emphasize starting the chosen 
prophylactic regimen at the first antenatal visit to 
avoid such missed opportunities; however, this 
recommendation is not without its drawbacks. 
For women for whom the 3-drug ARV prophylaxis 
is chosen, beginning this at the first antenatal visit 
neglects the importance of adequate treatment 
preparation prior to initiation. While starting earlier 
in pregnancy will clearly give more time for viral 
suppression to occur before delivery, and should 
therefore reduce the risk of transmission, this should 
not be done at the expense of proper treatment 
Option A: Maternal AZT  Option B: Maternal triple 
ARV Prophylaxis
Mother  Mother
n Antepartum AZT 

















*sd-NVP and AZT+3TC 
can be omitted if mother 
receives > 4 weeks AZT 
antepartum
 
Triple ARV from 14 weeks 
until 1 week after all 














Daily NVP from 
birth until 1 week 
after all exposure 






AZT or NVP for 6 
weeks
Breastfeeding infant
nDaily NVP from 
birth to 6 weeks
Non-breastfeeding infant
AZT or NVP for 6 
weeks
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preparation.  Doing so could lead to suboptimal 
adherence, development of resistance in the mother, 
and transmission of resistant virus to the child. 
For women receiving single-drug prophylaxis with 
AZT, there are no data to indicate that starting at 14 
weeks will reduce in utero transmission, and 
starting this early may potentially lead to increased 
maternal-fetal toxicity as well as the development of 
AZT resistance mutations.  Anemia in both women 
10 and infants exposed to AZT is well-documented.  
Other cytopenias (lymphopenia, neutropenia), 
which may persist for several years after birth and 
which are associated with duration of AZT 
11,12exposure,  and mitochondrial toxicities such as 
13,14hyperlactatemia and neurodevelopmental delay,  
have also been reported. 
Prolonged exposure to AZT monotherapy is likely 
to increase the frequency of AZT-associated 
resistance mutations in both women and their 
infants if transmission does occur, resulting in 
potentially compromised treatment options for 
both.  While one study from Thailand found no 
AZT-associated resistance in women starting short-
15
course prophylaxis at 34 weeks,  data from the US 
and Europe in the era of mono- and dual-therapy 
indicate that this will occur in a significant 
percentage of women and their children when ARV 
prophylaxis is started early in pregnancy.  Among 
293 women in the Perinatal AIDS Collaborative 
Transmission Study (PACTS) who received AZT 
during pregnancy, 17.3% of the women and 8% of 
their infected children had at least one AZT-
16
associated resistance mutation.   While a lower 
CD4 count was associated with the risk of 
developing resistance in this study, the median CD4 
3of women who had resistance was 389 cells/mm , 
suggesting that even women with CD4 > 350 remain 
at risk. Additionally, duration of ARV exposure was 
also significantly associated with resistance: at 24 
weeks, the median exposure among those who 
developed resistance is similar to what will occur if 
AZT is started at 14 weeks gestation.  AZT 
resistance was found in 25% of women from the 
Women and Infants Transmission Study (WITS), 
where – in contrast to the PACTS cohort – this 
resistance was associated with an increased risk of 
17 maternal-to-child transmission. Women from 
WITS had, however, lower average CD4 counts and 
higher viral loads than those in PACTS. 
The WHO argues that most women will not present 
as early as 14 weeks gestation, and that the goal of 
the current recommendation is to get women started 
on the appropriate prophylactic regimen during the 
nd2  trimester of pregnancy rather than waiting until 
late in pregnancy.  This makes sense, and we support 
initiation of 3-drug ARV prophylaxis as early in 
pregnancy as possible since it is likely to lead to 
improved suppression rates at the time of delivery 
and therefore decreased transmission.  However, we 
believe that it would be preferable to make a 
recommendation that explicitly states the ideal 
timing of and requisites for initiation of each option, 
rather than one that could lead to inadequate 
treatment preparation and an increased risk of 
toxicity and/or resistance. 
There is little debate about the need to provide 
effective prophylaxis during the breastfeeding 
period.  Most women in sub-Saharan Africa have no 
acceptable, feasible, affordable, safe, and 
sustainable (AFASS) alternative to breastfeeding, 
and HIV-free survival has not been shown to be 
18,19significantly greater even when they do.  
Furthermore, early weaning to reduce the period of 
HIV exposure has been shown to be associated with 
20
increased mortality.   It is therefore clear that most 
HIV-infected mothers in Zambia need to breastfeed 
their infants for at least one year.  The new 
guidelines provide two options for prophylaxis 
during this period: maternal 3-drug ARV (with 6 
weeks of infant prophylaxis) or ED-NVP for the 
infant, both of which are to continue until one week 
after breastfeeding cessation (see Table 3).   
Available data indicate that both strategies are 
21-23
effective,  though as noted previously the need for 
additional postnatal prophylaxis in infants born to 
mothers on 3-drug prophylaxis from early in 
pregnancy can be debated.  It should also be noted 
that, while it makes sense to continue ED-NVP for 
the entire duration of exposure, the safety and 
efficacy of this strategy has only been assessed up to 
18
6 months of life.  Daily infant administration of a 
drug whose dose needs frequent adjustment to 
remain effective may also prove challenging, and 
improper implementation of this strategy could lead 
to higher than expected rates of transmission and 
large numbers of children with acquired NVP-
resistance. 
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Finally, the regimen options listed for 3-drug 
prophylaxis include a triple-NRTI, which has been 
shown to have inferior viral suppression rates in 
adults  when compared to other 3-drug 
,
combinations.   Given this, it might be helpful for 
WHO to prioritize the different regimens listed. 
CONCLUSION 
In the fight against the global HIV epidemic, almost 
no battle is more critical than that against maternal-
to-child transmission of the virus.  The greatest 
reduction in such transmission will occur when the 
viral load is reduced to undetectable levels prior to 
delivery, and postnatal exposure in breast milk is 
eliminated.  In the industrialized world, where ART 
is recommended for all pregnant women and where 
safe alternatives to breastfeeding exist, rates of 
26
maternal-to-child transmission are < 2%.   Such 
dramatic reductions in transmission have been more 
difficult to achieve in Zambia and other resource-
constrained settings largely because access to ARVs 
is not as widespread, because HIV-infected pregnant 
women are often not started on prophylaxis until late 
in pregnancy, and because safe alternatives to breast 
milk do not exist for most families.  
To address these challenges, the revised 2009 WHO 
guidelines now recommend ART for all women with 
3
a baseline CD4 < 350 cells/mm , and give two 
options for those not in need of ART for their own 
health: antepartum AZT followed by ED-NVP 
during breastfeeding for the infant, or 3-drug 
maternal ARV prophylaxis starting early in 
pregnancy and continuing through the breastfeeding 
period.  
It is still not known which of the two ARV 
prophylaxis options will result in a greater reduction 
in transmission.  Currently available data suggest 
21-23,27-29
that they are similar,  but no direct comparative 
data exist.  IMPAACT 1077, a complex mutli-arm, 
randomized controlled trial has been designed to 
address this question and should shortly begin 
30
enrollment in multiple centers worldwide.  
Limitations of these new recommendations include 
an apparent under-emphasis on the need for 
adequate treatment preparation of pregnant women 
prior to beginning any treatment/prophylaxis option, 
and the risk of increased resistance due to prolonged 
antepartum exposure to AZT monotherapy – both of 
which could potentially result in compromised 
treatment options for women and their infected 
infants.   
In developing these guidelines, the WHO 
acknowledged that the feasibility of the different 
options will vary, and they encourage individual 
countries to adopt specific recommendations based 
on their socioeconomic situation.  In Zambia, where 
most women present to antenatal clinics later in 
pregnancy, where stigma still prevents some women 
from seeking HIV testing, and where CD4 
technology is not universally accessible, several 
challenges to effective implementation of these 
guidelines exist. 
N o n e t h e l e s s ,  t h e  r e v i s e d  2 0 0 9  W H O  
recommendations for the use of antiretroviral drugs 
for treating pregnant women and preventing HIV 
infection in children provide a reasonable, evidence-
based strategy that should significantly reduce new 
cases of pediatric HIV, resulting in healthier families 
and communities and a brighter future for Zambia. 
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